Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTa)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03679598 |
|
Recruitment Status :
Completed
First Posted : September 20, 2018
Last Update Posted : December 15, 2023
|
Sponsor:
University of Alabama at Birmingham
Collaborators:
National Institutes of Health (NIH)
Mereo BioPharma
Information provided by (Responsible Party):
Mark Dransfield, MD, University of Alabama at Birmingham
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 30, 2023 |
| Actual Study Completion Date : | December 1, 2023 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
June 7, 2024 |